Hypoglycemia was unusual and primarily noticed in patients concomitantly receiving insulin secretagogues or insulin, according to the glucose-dependent system of action. Serious hypoglycemia was unusual, supporting a favorable danger-reward profile for equally diabetic and non-diabetic populations.Continued refinement of formulation and dosing tact